(NP (NP-COOD (NP (JJ Aldosterone-specific) (NN membrane) (NNS receptors)) (CC and) (NP (NP (JJ rapid) (JJ non-genomic) (NNS actions)) (PP (IN of) (NP (NNS mineralocorticoids))))) (. .))
(S (NP-SBJ (NP (JJ Functional) (NNS studies)) (PP (IN in) (NP (NP (ADJP-COOD (ADJP (JJ extrarenal)) (, ,) (ADJP (JJ non-epithelial))) (NNS cells)) (PP (JJ such) (IN as) (NP-COOD (NP (JJ smooth) (NN muscle) (NNS cells)) (CC and) (NP (ADVP-TMP (RBR more) (RB recently)) (VBG circulating) (JJ human) (NNS lymphocytes))))))) (VP (VBP have) (VP (VBN provided) (NP (VBG increasing) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NN aldosterone)) (VP (VBZ produces) (NP (NP-COOD (CONJP (RB not) (RB only)) (NP (JJ classical) (JJ genomic) (NNS effects)) (, ,) (CONJP (CC but) (RB also)) (NP (ADJP-COOD (ADJP (JJ rapid)) (, ,) (ADJP (JJ non-genomic))) (NNS effects))) (PP (IN on) (NP (NN transmembrane) (NN electrolyte) (NNS movements)))))))))) (. .))
(S (NP-SBJ (DT These)) (VP (VBP involve) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (NN (proton sodium)) (NN exchanger)) (PP (IN of) (NP (DT the) (NN cell) (NN membrane))))) (PP (IN at) (NP (NP (ADJP-COOD (ADJP (RB very) (JJ low)) (, ,) (ADJP (JJ physiological))) (NNS concentrations)) (PP (IN of) (NP (NN aldosterone))))) (PP (IN with) (NP (NP (DT an) (JJ acute) (NN onset)) (PP-TMP (IN within) (NP (QP (CD 1-2)) (NN min))))))) (. .))
(S (NP-SBJ (NP (DT A) (JJ second) (NN messenger) (NN cascade)) (VP (VBN involved) (NP (-NONE- *)))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN inositol) (NN (calcium 1,4,5-trisphosphate)) (NN pathway)) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ (-NONE- *T*-1)) (VP (VBZ responds) (PP-TMP (IN over) (NP (DT the) (JJ same) (JJ rapid) (NN time) (NN course)))))))) (. .))
(S (NP-SBJ-2 (JJ Such) (NNS changes)) (ADVP (RB clearly)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN explained) (NP (-NONE- *-2)) (PP (IN by) (NP-LGS (NP (JJ genomic) (NNS mechanisms)) (, ,) (SBAR (WHNP-3 (WDT which)) (S (NP-SBJ (-NONE- *T*-3)) (VP (VBP are) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (JJ later) (NNS effects)) (PP (IN than) (NP (DT the) (ADJP (NP (NN membrane)) (JJ related)) (JJ rapid) (NNS responses)))))))))))))) (. .))
(S (NP-SBJ-4 (NP (DT The) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT these) (JJ rapid) (NNS effects)) (PP (IN of) (NP (NN aldosterone))) (PP (IN on) (NP (NNS electrolytes)))))) (VP (VBP have) (VP (VBN been) (ADVP (RB extensively)) (VP (VBN studied) (NP (-NONE- *-4)) (PP (IN in) (NP (NP (JJ human) (NNS lymphocytes)) (, ,) (SBAR (WHNP-5 (WDT which)) (S (ADVP (RB thus)) (NP-SBJ (-NONE- *T*-5)) (VP (MD may) (VP (VB represent) (NP (NP (JJ valuable) (NNS tools)) (PP (IN in) (NP (NP (DT the) (NN delineation)) (PP (IN of) (NP (NP (DT the) (JJ receptor-effector) (NNS mechanisms)) (VP (VBN involved) (NP (-NONE- *))))))))))))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ unique) (NNS characteristics)) (PP (IN of) (NP (NP (DT this) (JJ new) (NN pathway)) (PP (IN for) (NP (NN steroid) (NN action)))))) (VP (VBP include) (NP-COOD (NP (PRP$ its) (JJ rapid) (NN time) (NN course)) (, ,) (NP (NP (JJ 10,000-fold) (NN selectivity)) (PP (IN for) (NP (NN aldosterone))) (PP (IN over) (NP (NN cortisol)))) (CC and) (NP (NP (DT the) (NN ineffectiveness)) (PP (IN of) (NP (NP (NNS spironolactones)) (, ,) (NP (JJ classical) (NN mineralocorticoid) (NNS antagonists)) (, ,))) (PP (IN as) (NP (NP (NNS antagonists)) (PP (IN of) (NP (DT the) (NN response)))))))) (. .))
